BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  HTG Molecular Diagnostics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Tuesday, November 7

  Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.

  October 20, 2017

   · 

  1 min read
• Drug Development

  Spring Bank Pharmaceuticals Announces Additional Inarigivir (Formerly SB 9200) Results From the ACHIEVE Trial in HBV Patients at AASLD Conference

  The Data Safety Monitoring Board approves proceeding with enrollment of third cohort (inarigivir 100mg) of the ACHIEVE trial.

  October 20, 2017

   · 

  6 min read
• 

  Policy

  AzurRx BioPharma and Mayoly Spindler Announce MS1819-SD Investigational Medicinal Product Dossier (IMPD) Submission

  This IMPD has been submitted through the EMA clinical trial portal for approval prior to opening of clinical centers in France.

  October 20, 2017

   · 

  4 min read
• Florida International University Release: Can Adults Develop ADHD? Research Says Probably Not

  Adults likely do not develop ADHD, according to new research by FIU clinical psychologist Margaret Sibley.

  October 20, 2017

   · 

  1 min read
• Pharm Country

  RenovaCare Announces Successful Closing of Financing

  RenovaCare announced the closing of its previously announced registered direct offering of 915,000 shares of its common stock at a an offering price of $2.50 per share and its concurrent private placement of common stock purchase warrants (the “Warrants” to purchase 915,000 shares of common stock.

  October 20, 2017

   · 

  7 min read
• Drug Development

  VBL Therapeutics Announces Orphan Drug Designation for VB-111 in Europe

  The EMA has designated ofranergene obadenovec (VB-111) as an ‘orphan medicinal product’ for the treatment of ovarian cancer.

  October 20, 2017

   · 

  4 min read
• Drug Development

  RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer

  The Orphan Drug designation allows RedHill to benefit from various development incentives to develop MESUPRON for this indication.

  October 20, 2017

   · 

  9 min read
• Biotech Beach

  CombiMatrix to Present New Data From a Large-Scale Analysis of Genomic Abnormalities Impacting Multiple Stages of Human Growth and Development Starting from Conception through Childhood at the American Society of Human Genetics Annual Meeting

  Results from nearly 32,000 samples analyzed in this study indicate that genomic alterations decrease in frequency and severity from conception through development into childhood.

  October 20, 2017

   · 

  6 min read
• Business

  Five Prime Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 6

  Five Prime will host a conference call and live audio webcast on Monday, November 6, 2017, at 4:30 p.m. (ET)/1:30 p.m. (PT) to discuss the company’s financial results and provide a general business update.

  October 20, 2017

   · 

  1 min read
• BioCapital

  Osiris Therapeutics to Present 10 Advanced Clinical and Scientific Abstracts, Including an Exclusive Oral Presentation on its New Ambient Viable Tissue Preservation Technology

  Experts to host a variety of presentations at Symposium on Advanced Wound Care Fall Meeting, October 20 to 22, 2017, in Las Vegas, Nevada.

  October 20, 2017

   · 

  6 min read